Structure - based drug design, in which the physical structure of a targeted protein is used to help identify compounds that will interact with it, has already been used to
generate therapeutic agents for a number of infectious and metabolic diseases.
Not exact matches
Originally described in the 1980s, the potential of oligonucleotides as
therapeutic agents spawned hundreds of clinical trials and billions of dollars of investment in companies developing these therapeutics without
generating successful products.
The researchers plan to intensively study the immune responses
generated by
therapeutic vaccines, broadly neutralizing antibodies, and latency reversing
agents in both acutely infected individuals and also in preclinical studies.